Synergy and Mechanisms of Monoclonal Antibody-Chemotherapy in NSCLC

Yihui Chen

doi:10.54097/2977x191

Authors

Yihui Chen

DOI:

https://doi.org/10.54097/2977x191

Keywords:

Monoclonal antibodies; chemotherapy; synergistic mechanism.

Abstract

Lung cancer is the most prevalent and lethal malignant tumor worldwide, with non-small cell lung cancer (NSCLC) accounting for 80%-85% of cases. Most NSCLC patients are diagnosed at an advanced stage, losing curative surgical chances, making improving treatment efficacy and survival a critical clinical challenge. This study systematically reviews the research progress of monoclonal antibody (mAb) combined with chemotherapy for NSCLC, analyzes their synergistic mechanisms, and evaluates the therapy’s clinical efficacy and safety. Internationally, trials like KEYNOTE-189 and ECOG 4599 confirmed the efficacy of mAb-chemotherapy, while domestically, the BEYOND trial validated bevacizumab-based combinations in Chinese patients. Representative monoclonal antibodies such as cetuximab, bevacizumab, and pembrolizumab exert their therapeutic effects through receptor blockade, anti-angiogenesis, or immune checkpoint inhibition. When combined with chemotherapy, these agents can prolong overall survival and improve response rates in patients, albeit with an increased incidence of adverse events (e.g., hemorrhage, immune-related adverse reactions). The synergistic mechanisms involve enhanced chemosensitivity, immune modulation, and co-inhibition of molecular signaling pathways, though gaps remain in mechanistic understanding and optimization of primary treatment protocols. This study provides scientific rationale for clinical decision-making and novel therapeutic strategies, advancing the field of non-small cell lung cancer treatment.

Downloads

Download data is not yet available.

References

[1] Garassino, M. C., et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Journal of Clinical Oncology, 2023, 41(11), 1992–1998.

[2] Tyagi P. Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial. Clinical lung cancer, 2005, 6(5), 276–278.

[3] Wheeler, D. L., et al. Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nature Reviews Clinical Oncology, 2010, 7(9), 493-507.

[4] Ferrara, N., et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery, 2004, 3(5), 391-400.

[5] Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012, 366(26):2455-2465.

[6] Beck, A., et al. Strategies and challenges for the next generation of antibody–drug conjugates. Nature Reviews Drug Discovery, 2017, 16(5), 315-337.

[7] Reck, M., et al. Pembrolizumab versus chemotherapy for PD–L1–positive–small-cell lung cancer. New England Journal of Medicine, 2016, 375(19), 1823–1833.

[8] Seto, T., et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. The Lancet Oncology, 2014, 15(11), 1236–1244.

[9] Saito, H., et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. The Lancet Oncology, 2019, 20(5), 625–635.

[10] Novello, S., et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology, 2023, 41(11), 1999–2006.